Readoutin 45d
Merck Sharp & Dohme LLC — Pembrolizumab
Phase 3 primary completion: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992).
- Date
- Jan 2027
- Type
- Readout
- Indication
- Urinary Bladder Neoplasms